Cargando…

CAR-T cell therapy: current limitations and potential strategies

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sterner, Robert C., Sterner, Rosalie M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024391/ https://www.ncbi.nlm.nih.gov/pubmed/33824268 http://dx.doi.org/10.1038/s41408-021-00459-7

Ejemplares similares

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

Immune response following traumatic spinal cord injury: Pathophysiology and therapies
por: Sterner, Robert C., et al.
Publicado: (2023)

A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy
por: Sterner, Rosalie M., et al.
Publicado: (2020)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
por: Zhang, Xiaomin, et al.
Publicado: (2023)

CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies
por: To, Van, et al.
Publicado: (2022)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
por: Huang, Jiawen, et al.
Publicado: (2022)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

The Pathogenesis of Lupus Nephritis
por: Sterner, Rosalie M., et al.
Publicado: (2014)

Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

CAR-T cell therapy: a potential new strategy against prostate cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

Current progress in CAR-T cell therapy for tumor treatment
por: Chen, Lei, et al.
Publicado: (2022)

Contrast medium-induced nephropathy. Aspects on incidence, consequences, risk factors and prevention
por: Sterner, Gunnar, et al.
Publicado: (2007)

Current status and hurdles for CAR-T cell immune therapy
por: Zhao, Ruocong, et al.
Publicado: (2019)

Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
por: Mancikova, Veronika, et al.
Publicado: (2021)

CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
por: Kankeu Fonkoua, Lionel A., et al.
Publicado: (2022)

Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
por: Jo, Yuna, et al.
Publicado: (2020)

Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors
por: Alcantara, Marion, et al.
Publicado: (2020)

Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
por: Mulgaonkar, Aditi, et al.
Publicado: (2023)

Donor T cells for CAR T cell therapy
por: Tang, Tiffany C. Y., et al.
Publicado: (2022)

Mending a broken heart: current strategies and limitations of cell-based therapy
por: Liew, Lee Chuen, et al.
Publicado: (2020)

CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
por: Thomas, Pauline, et al.
Publicado: (2021)

CAR‐T cell therapy for lung cancer: Potential and perspective
por: Chen, Long, et al.
Publicado: (2022)

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
por: Rendo, Matthew J, et al.
Publicado: (2022)

Mechanisms of CAR T cell exhaustion and current counteraction strategies
por: Zhu, Xiaoying, et al.
Publicado: (2022)

Current Progress of CAR-NK Therapy in Cancer Treatment
por: Pang, Zhaojun, et al.
Publicado: (2022)

CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement
por: Pant, Ayush, et al.
Publicado: (2023)

Clinical characteristics, management, and outcomes of patients with primary cardiac angiosarcoma: A systematic review
por: Chambergo-Michilot, Diego, et al.
Publicado: (2023)

Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
por: Liu, Qianzhen, et al.
Publicado: (2022)

Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies
por: Zhang, Yugu, et al.
Publicado: (2023)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Current Advances in CAR T Cell Therapy for Malignant Mesothelioma
por: Klampatsa, Astero, et al.
Publicado: (2020)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings
por: Scanlon, Michael L, et al.
Publicado: (2013)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
por: Asmamaw Dejenie, Tadesse, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hqh4i18omu1p3f6fk96o80s43b